anthracycline

Type: Keyphrase
Name: anthracycline
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Halaven® (Eribulin) Now Commercially Available in Lebanon for the Treatment of Metastatic Breast Cancer

HATFIELD, England Eisai partners with Abela Frères for the commercialisation of Halaven® (eribulin)Eisai EMEA (EuropeAround 1,750 women in LebanonToshitaka Asano"We are committed to building a strong relationship with Eisai to ensure that Halaven reaches ... [Published ADVFN UK - Apr 07 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether drug major Bayer’s (BAYN: DE) Xofigo (radium-223 dichloride) ... [Published Pharma Letter - Apr 04 2014]
First reported Apr 03 2014 - Updated Apr 04 2014 - 1 reports

Radium-223 dichloride in prostate cancer: Major added benefit for certain patients

( Institute for Quality and Efficiency in Health Care ) Trastuzumab emtansine: indication of major added benefit in metastatic breast cancer with previous anthracycline therapy. Appropriate comparator therapy was only complied with in one out of four ... [Published Infrosoft - Apr 03 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Neuroprotective iron chelators and pharmaceutical compositions comprising them

Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular ... [Published Free Patents Online - Apr 01 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 4 reports

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of SAVENE ® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms ... [Published News-Medical.Net - Mar 31 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Gem Pharmaceuticals Announces $4.5 Million Financing

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Gem Pharmaceuticals announced that current Gem boardmembers/investors Diane Hendricks and Karl Leo have agreed to provide up to $4.5 million in new capital in order to fund the ... [Published NewsRX - Mar 28 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Gem Pharmaceuticals Announces $4.5 Million Financing

By a News Reporter-Staff News Editor at Biotech Week -- Gem Pharmaceuticals announced that current Gem boardmembers/investors Diane Hendricks and Karl Leo have agreed to provide up to $4.5 million in new capital in order to fund the Company's upcoming ... [Published HispanicBusiness.com - Mar 26 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 3 reports

Obesity and diabetes have adverse effects on cancer outcomes

Both obesity and diabetes have adverse effects on outcomes in breast cancer patients who receive chemotherapy as primary treatment before surgery (neoadjuvant chemotherapy), according to research to be presented at the 9th European Breast Cancer Conference ... [Published Bio-Medicine - Mar 20 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 2 reports

Gem Pharmaceuticals nabs $4.5 mln

Gem Pharmaceuticals said Wednesday that it has received $4.5 million in funding. The investors were current board members Diane Hendricks and Karl Leo. Based in Birmingham, Alabama, Gem Pharmaceuticals is a clinical-stage biopharmaceutical company ... [Published PE Hub Blog - Mar 19 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 3 reports

Genentech’s Kadcyla Helped People With Advanced HER2-Positive Breast Cancer Live Longer Without Their Disease Worsening in New Phase III Study

/ Media / Press ReleasesFriday, Sep 27, 2013Phase III TH3RESA study results will be presented today at the European Cancer Congress in Amsterdam Kadcyla nearly doubled the time that people lived without their disease worsening compared with treatment ... [Published Genentech - Mar 19 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 1 reports

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and ...

This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC).Methods: Eligible patients received sunitinib 37.5 mg/day and trastuzumab administered either ... [Published 7thSpace - Mar 07 2014]
First reported Feb 23 2014 - Updated Feb 23 2014 - 1 reports

Pharmaceutical Research Interindividual Variability in the Cardiac Expression of Anthracycline Reductases in Donors With and Without Down Syndrome

Type: Original PaperPurposeThe intracardiac synthesis of anthracycline alcohol metabolites (e.g., daunorubicinol) contributes to the pathogenesis of anthracycline-related cardiotoxicity. Cancer patients with Down syndrome (DS) are at increased risk f ... [Published BioPortfolio - Feb 23 2014]

Quotes

...According to news reporting from London UnitedUnited Kingdom, by NewsRx journalists, research stated, "Combination antiretroviral therapy (cART) is standard of care for patients with HIV diagnosed with Kaposi's sarcoma (KS), but the current role of systemic chemotherapy is undefined. Since 1998, a prospective stage-stratified approach has been adopted for 469 patients with HIV with KS."
...Peter Stein, chief executive officer at Norgine, said: "Following a comprehensive strategic review, we believe this transaction represents an excellent outcome to maximise access to Savene for those patients who need it." This comes after Norgine announced last month that it has commenced a phase IIb trial of a new faecal incontinence therapy, in association with partner...
"We are committed to building a strong relationship with Eisai to ensure that Halaven reaches the people who need it in Lebanon,” said Antoine Fadel, Chief Executive Officer, Abela Frères. “Our extensive marketing and distribution experience in the region best positions us for this partnership.”"
"We are committed to building a strong relationship with Eisai to ensure that Halaven reaches the people who need it in Lebanon"

More Content

All (50) | News (46) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
ONLINE FIRDST: APL: Warnings that Even with Suc... [Published Oncology Times - Apr 11 2014]
Accidental Extravasation of Chemotherapy [Published The ASCO Post - Apr 11 2014]
Targeting of bone marrow neovasculature [Published PharmCast - Apr 11 2014]
Nektar Presents Pipeline Data [Published Zacks.com - Apr 10 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
Studies from Chelsea and Westminster Hospital N... [Published AEGIS - Apr 08 2014]
Norgine and SpePharm to sell Savene to Clinigen [Published Zenopa - Apr 08 2014]
HALAVEN® (ERIBULIN) NOW COMMERCIALLY AVAILABLE ... [Published PharmiWeb - Apr 08 2014]
Trastuzumab emtansine: indication of major adde... [Published EurekAlert! - Apr 07 2014]
Halaven® (Eribulin) Now Commercially Available ... [Published ADVFN UK - Apr 07 2014]
Germany’s IQWiG views Xofigo, Kadcyla and Eviplera [Published Pharma Letter - Apr 04 2014]
Radium-223 dichloride in prostate cancer: Major... [Published Infrosoft - Apr 03 2014]
Showcase, April 2014 [Published Pharmacist.com - Apr 01 2014]
Neuroprotective iron chelators and pharmaceutic... [Published Free Patents Online - Apr 01 2014]
Clinigen Group announces acquisition of SAVENE ... [Published News-Medical.Net - Mar 31 2014]
Clinigen acquires Savene [Published MoneyAM - Mar 31 2014]
Clinigen : Acquires Oncology Support Therapy SA... [Published 4 Traders - Mar 31 2014]
Clinigen Group Acquires Oncology Support Therap... [Published Business Wire Health News - Mar 31 2014]
Gem Pharmaceuticals Announces $4.5 Million Fina... [Published NewsRX - Mar 28 2014]
Relapsed Small Cell Lung Cancer [Published General Medicine eJournal - Mar 28 2014]
Gem Pharmaceuticals Announces $4.5 Million Fina... [Published HispanicBusiness.com - Mar 26 2014]
Obesity, diabetes have adverse effects on outco... [Published Science Daily - Mar 24 2014]
Amrubicin combination fails in phase III trial [Published Oncology Report - Mar 24 2014]
Human medicines European public assessment repo... [Published European Medicines Agency - Mar 20 2014]
Obesity and diabetes have adverse effects on ca... [Published Bio-Medicine - Mar 20 2014]
EBCC 9: Obesity and diabetes and should be take... [Published Ecancer Medicalscience - Mar 20 2014]
Chemotherapy decisions [Published Australian Doctor - Mar 20 2014]
Cancer Treatment : Patent Issued for Antineopla... [Published 4 Traders - Mar 20 2014]
Gem Pharmaceuticals nabs $4.5 mln [Published PE Hub Blog - Mar 19 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Clinigen Group Acquires Oncology Support Therap... [Published Business Wire Health News - Mar 31 2014]
BURTON-ON-TRENT, England--(BUSINESS WIRE)--Clinigen Group plc (‘Clinigen’ or the ‘Group’) (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate ...
Gem Pharmaceuticals nabs $4.5 mln [Published PE Hub Blog - Mar 19 2014]
Gem Pharmaceuticals said Wednesday that it has received $4.5 million in funding. The investors were current board members Diane Hendricks and Karl Leo. Based in Birmingham, Alabama, Gem Pharmaceuticals is a clinical-stage biopharmaceutical company ...
Trastuzumab And Anthracyclines Do Not Need To B... [Published Scientific Blogging - Medicine - Nov 13 2013]
Trastuzumab and anthracyclines given concurrently are effective at treating HER-2-positive breast cancer but there is worry that this could lead to increased risk of cardiac toxicity. New research shows these agents do not need to be given concurrently ...
So chemotherapy does work, after all (revisited... [Published ScienceBlogs : Combined Feed - Oct 30 2013]
If there’s one medical treatment that proponents of “alternative medicine” love to hate, it’s chemotherapy. Rants against “poisoning” are a regular staple on “alternative health” websites, usually coupled with insinuations or outright accusations that ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.